1st Quarter - Report

MEHLMAN CONSULTING, INC. for VIZIENT INC

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Healthcare coverage; prescription drug costs; group purchasing issues; drug shortage issues. 340B Drug Pricing Program. COVID supply chain issues. H.R. 1319 - American Rescue Plan Act of 2021; P.L. 117-2.

LobbyistCovered position, as disclosed
LAUREN ARONSON —
DEAN ROSEN —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; White House Office; Office of the Vice President of the United States; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); SENATE

Bills named: H.R. 1319 (117th)

Medicare/Medicaid MMM

Healthcare transparency, costs and access to affordable medication and other healthcare items and services. H.R. 1319 - American Rescue Plan Act of 2021; P.L. 117-2.

LobbyistCovered position, as disclosed
LAUREN ARONSON —
DEAN ROSEN —

Contacted: Office of the Vice President of the United States; Centers For Medicare and Medicaid Services (CMS); White House Office; Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: H.R. 1319 (117th)

Pharmacy PHA

Issues related to Unapproved Drug Initiative.

LobbyistCovered position, as disclosed
LAUREN ARONSON —
DEAN ROSEN —

Contacted: White House Office; SENATE; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Office of the Vice President of the United States

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.